[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]

January 16, 2018, Vol 319, No. 3, Pages 205-316 | Obesity

In This Issue of JAMA

Highlights

Abstract Full Text
free access has audio
JAMA. 2018;319(3):205-207. doi:10.1001/jama.2017.12196
Viewpoint

Evolving Societal Norms of ObesityWhat Is the Appropriate Response?

Abstract Full Text
JAMA. 2018;319(3):221-222. doi:10.1001/jama.2017.18947

This Viewpoint discusses shifts in social norms toward acceptance of obesity as normal and proposes harnessing the same peer effects that have destigmatized obesity to promote and spread healthy behaviors.

Toward Precision Approaches for the Prevention and Treatment of Obesity

Abstract Full Text
JAMA. 2018;319(3):223-224. doi:10.1001/jama.2017.20051

This Viewpoint discusses the prospects for treatment of obesity through identification of genetic, metabolic, behavioral, and environmental risk factors and an understanding of factors that account for variability in the success of treatment.

Counting Calories as an Approach to Achieve Weight Control

Abstract Full Text
JAMA. 2018;319(3):225-226. doi:10.1001/jama.2017.21355

This Viewpoint discusses approaches that clinicians can take when advising overweight or obese patients to achieve weight control via calorie reduction.

Can the Government Require Health Warnings on Sugar-Sweetened Beverage Advertisements?

Abstract Full Text
JAMA. 2018;319(3):227-228. doi:10.1001/jama.2017.19209

This Viewpoint uses the 2017 Ninth Circuit ruling enjoining San Francisco from requiring a health warning statement on sugar-sweetened beverages to discuss modifications that would make the warnings legally justifiable.

Taxes and Sugar-Sweetened Beverages

Abstract Full Text
JAMA. 2018;319(3):229-230. doi:10.1001/jama.2017.19522

This Viewpoint discusses the merits and challenges to implementing taxes on sugar-sweetened beverages aimed at reducing their consumption in an effort to curb US obesity rates.

Fitness or FatnessWhich Is More Important?

Abstract Full Text
JAMA. 2018;319(3):231-232. doi:10.1001/jama.2017.21649

This Viewpoint reviews evidence comparing the relative importance of cardiorespiratory fitness and obesity with all-cause and cardiovascular disease–related mortality, and calls for accurate measures of physical activity and fitness in future studies investigating associations between obesity and mortality.

A Piece of My Mind

Engaging With Patients on Health Policy ChangesAn Urgent Issue

Abstract Full Text
free access
JAMA. 2018;319(3):233-234. doi:10.1001/jama.2017.20257

In this essay, Jerry Avorn considers physicians’ social responsibility to initiate discussions with their patients about changes in health policy proposed by politicians that will affect patients' quality and continuity of care.

Editorial

Comparing the Outcomes of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass for Severe Obesity

Abstract Full Text
has audio
JAMA. 2018;319(3):235-237. doi:10.1001/jama.2017.20449

Reimagining Obesity in 2018A JAMA Theme Issue on Obesity

Abstract Full Text
has audio
JAMA. 2018;319(3):238-240. doi:10.1001/jama.2017.21779
Original Investigation

Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid ObesityThe SLEEVEPASS Randomized Clinical Trial

Abstract Full Text
has active quiz
JAMA. 2018;319(3):241-254. doi:10.1001/jama.2017.20313

This study reports 5-year weight loss outcomes for participants in the SLEEVEPASS equivalence trial with morbid obesity managed with laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass.

Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid ObesityThe SM-BOSS Randomized Clinical Trial

Abstract Full Text
JAMA. 2018;319(3):255-265. doi:10.1001/jama.2017.20897

This randomized clinical trial compares the effects of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on 5-year excess weight loss in patients with morbid obesity.

Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study

Abstract Full Text
has active quiz
JAMA. 2018;319(3):266-278. doi:10.1001/jama.2017.20813

This report describes 5-year blood pressure, Hemoglobin A1c, and lipid levels among participants previously randomized to Roux-en-Y gastric bypass surgery vs no surgery for management of obesity and type 2 diabetes.

Association of Bariatric Surgery Using Laparoscopic Banding, Roux-en-Y Gastric Bypass, or Laparoscopic Sleeve Gastrectomy vs Usual Care Obesity Management With All-Cause Mortality

Abstract Full Text
has active quiz
JAMA. 2018;319(3):279-290. doi:10.1001/jama.2017.20513

This cohort study uses Israeli electronic health record data to compare mortality of obese adult patients who underwent bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy) vs obese adults receiving nonsurgical usual care management.

Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities

Abstract Full Text
JAMA. 2018;319(3):291-301. doi:10.1001/jama.2017.21055

This cohort study uses Norwegian registry data to compare long-term changes in hypertension, diabetes, depression, and opioid use among patients with severe obesity treated with bariatric surgery or specialized medical treatment.

From The JAMA Network

Long-term Outcomes Following Bariatric Surgery

Abstract Full Text
JAMA. 2018;319(3):302-303. doi:10.1001/jama.2017.20521

This commentary discusses a study published in JAMA Surgery reporting 7-year weight and health outcomes for patients in the Longitudinal Assessment of Bariatric Surgery (LABS) Study who underwent Roux-en-Y gastric bypass or laparoscopic adjustable gastric banding.

Research Letter

Pass-Through of a Tax on Sugar-Sweetened Beverages at the Philadelphia International Airport

Abstract Full Text
JAMA. 2018;319(3):305-306. doi:10.1001/jama.2017.16903

This study estimates how much the 1.5¢-per-ounce tax on sugar-sweetened beverages in Philadelphia raised retail prices of soft drinks at the Philadelphia International Airport 1 month after implementation.

Comment & Response

Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer

Abstract Full Text
JAMA. 2018;319(3):306. doi:10.1001/jama.2017.18312

Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer—Reply

Abstract Full Text
JAMA. 2018;319(3):306-307. doi:10.1001/jama.2017.18318

Trends in Carotid Revascularization Procedures

Abstract Full Text
JAMA. 2018;319(3):307-308. doi:10.1001/jama.2017.19773

Trends in Carotid Revascularization Procedures

Abstract Full Text
JAMA. 2018;319(3):308. doi:10.1001/jama.2017.19769

Trends in Carotid Revascularization Procedures—Reply

Abstract Full Text
JAMA. 2018;319(3):308-309. doi:10.1001/jama.2017.19781

Risks of Statins for Lower-Risk Individuals

Abstract Full Text
JAMA. 2018;319(3):309-310. doi:10.1001/jama.2017.19170

Risks of Statins for Lower-Risk Individuals—Reply

Abstract Full Text
JAMA. 2018;319(3):310. doi:10.1001/jama.2017.19174
Medical News & Perspectives

Interest in the Ketogenic Diet Grows for Weight Loss and Type 2 Diabetes

Abstract Full Text
free access
JAMA. 2018;319(3):215-217. doi:10.1001/jama.2017.20639

This Medical News article discusses clinical use of a very-low-carb, high-fat diet for weight loss and type 2 diabetes treatment.

Global Health

Possible Biomarkers of Deadly Ebola

Abstract Full Text
free access
JAMA. 2018;319(3):219. doi:10.1001/jama.2017.20420

Dangers of Substandard or Falsified Medicines

Abstract Full Text
free access
JAMA. 2018;319(3):219. doi:10.1001/jama.2017.21291

Combination Strategy Associated With Reduced HIV Incidence in Uganda

Abstract Full Text
free access
JAMA. 2018;319(3):219. doi:10.1001/jama.2017.21296
News From the Food and Drug Administration

Second Cancer Biosimilar Approved

Abstract Full Text
free access
JAMA. 2018;319(3):220. doi:10.1001/jama.2017.20642

Regulatory Pathway for 3D Printing

Abstract Full Text
free access
JAMA. 2018;319(3):220. doi:10.1001/jama.2017.20643

Monthly Buprenorphine Injection Approved for Opioid Use Disorder

Abstract Full Text
free access
JAMA. 2018;319(3):220. doi:10.1001/jama.2017.20647
JAMA Infographic

Medical Care Use and Expenditures Associated With Adult Obesity in the United States

Abstract Full Text
free access
JAMA. 2018;319(3):218. doi:10.1001/jama.2017.21063
Poetry and Medicine

EmbersPET CT Skull Base to Mid Thighs

Abstract Full Text
JAMA. 2018;319(3):311. doi:10.1001/jama.2017.6553
JAMA Revisited

Appropriations for City Health Departments

Abstract Full Text
JAMA. 2018;319(3):312. doi:10.1001/jama.2017.12204
JAMA Patient Page

Sleeve Gastrectomy for Weight Loss

Abstract Full Text
free access
JAMA. 2018;319(3):316. doi:10.1001/jama.2017.18519

This JAMA Patient Page describes the sleeve gastrectomy procedure as a weight loss treatment for obese persons.

JAMA Masthead

JAMA

Abstract Full Text
free access
JAMA. 2018;319(3):209-210. doi:10.1001/jama.2017.12197
×